



ASX and Media Release

16 August 2011

Securities trading in ASX code VLA will resume trading on 18 August (post consolidation)

Viralytics Limited (ASX: VLA, OTC: VRACY)

In accordance with the previously published timetable, the 1 for 10 share and option consolidation was completed today and post-consolidation shares (ASX code: **VLA**) will commence normal trading (T+3 settlement basis) on 18 August 2011. Until that time, the Company's shares can be traded under the temporary share code: VLADA. On 18 August 2011, the share code will revert to VLA.

The pre-consolidation securities previously on issue were as follows:

Description	Number of Securities
Pre-consolidation Shares – ORD	590,362,227
Pre-consolidation Options	18,500,000

The post-consolidation securities now on issue are as follows:

Description	Number of Securities
Post-consolidation Shares – ORD	59,036,726
Post-consolidation Options (<i>including the issue of 2,900,000 options as approved at the EGM held on 2 August 2011</i>)	4,750,000

Note: The total consolidated ordinary shares include rounding of 504 shares.

Holding statements will be mailed to shareholders on 17 August 2011.

Jennie Yuen
Company Secretary
Viralytics Limited

About Viralytics Ltd: Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAK™ is the trade name for Viralytics' proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells, using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF) to bind and infect target cells. Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others. EV1 uses the receptor, integrin $\alpha 2 \beta 1$ (alpha 2 beta 1) receptor to bind and infect target cells. Integrin $\alpha 2 \beta 1$ (alpha 2 beta 1) has been demonstrated to be highly expressed on multiple cancer types, including: prostate cancer, ovarian cancer and others.